More Mesoblast Limited news
Mesoblast LimitedASX: MSB

Mesoblast Phase 2 Diabetic Kidney Disease Results Published

Oct 6, 2016 at 1:36 AM EDT · Issued by Mesoblast Limited

Filed with ASX · Oct 6, 2016 at 1:36 AM EDT · 3 pages · English

On 6ix: 6ix.com/news/mesoblast-phase-2-diabetic-kidney-disease-results-published

Watch Mesoblast's latest callMesoblast (ASX:MSB) Q4 2026 Earnings Call · Replay · Aug 26↗

Mesoblast Limited on 6ix

Story so far

  • CHF Phase 2 Trial Results Published In Circulation ResearchFeb 11, 2016
  • Type 2 Diabetes Trial Results Published In Diabetes CareFeb 11, 2016

Earlier from Mesoblast

  • Preliminary Final Report (Including Appendix 4E)Aug 24, 2016
  • MSB Strengthens US Patent Portfolio For Rheumatic DiseasesAug 16, 2016
  • Mesoblast P2 Results Show Dose-Related Improvements In RAAug 8, 2016
  • MSB Back Pain Results Presented, Receive Best Science AwardAug 1, 2016
  • Update on Heart Failure Trial and Funding of OperationsJul 1, 2016

Later from Mesoblast

  • MSB Japan Strategy Highlighted At Business Council MeetingOct 12, 2016
  • Successful Interim Futility Analysis In P3 Trial for GVHDNov 13, 2016
  • First Quarter Results On Form 6KNov 14, 2016
  • MD Anderson and NIH Fund Trial Using Mesoblast TechnologiesDec 6, 2016
  • Mesoblast And Mallinckrodt Enter Into AgreementDec 22, 2016
All Mesoblast news releases↗

Follow Mesoblast into a list and get an email when it puts out news.

Follow Mesoblast
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer